A major contributor to this article appears to have a close connection with its subject. (January 2021) |
Jeffery Daniel Molkentin (born January 15, 1967, in Milwaukee, Wisconsin) is an American molecular biologist.[1] He is the director of Molecular Cardiovascular Biology for Cincinnati Children's hospital where he is also co-director of their Heart Institute.[2] Molkentin holds a professorship at the University of Cincinnati's Department of Pediatrics.[3][4]
Jeffery Daniel Molkentin | |
|---|---|
 | |
| Born | January 15, 1967 Milwaukee, Wisconsin, U.S. |
| Alma mater | Marquette University |
| Scientific career | |
| Fields | Molecular biology |
Biography
editMolkentin was born and raised in Milwaukee, Wisconsin.,[1] where he attended Marquette University, receiving a B.S. in biology in 1989. He began studies to be a medical doctor at the University of Wisconsin,[2] but switched to a research program, and received his PhD in physiology from the Medical College of Wisconsin in 1994.[1]
Molkentin's work focuses on heart disease and muscular dystrophy, though he is involved in other types of research entailing calcium handling, ER stress signaling, cardiac hypertrophic signaling pathways,[5] and COVID-19 disease mechanisms.[6] One of Molkentin's most notable research achievements was his contribution to stem cell therapy in the heart and his disproving prior research about the topic.[7][8]
Molkentin is among the most highly cited researchers in the world, with a Scopus h-index of 130 and a Google Scholar h-index of 156.[9][10] Molkentin is ranked 170th most cited Biology and Biochemistry researcher out of 30,000 scientists in the Research.com database.[11] His work has been published in several prestigious research journals, including "Nature",[12] "PNAS",[13] "Circulation Research",[14] and "Cell".[15]
Molkentin was a full investigator for the Howard Hughes Medical Institute (HHMI) from 2008 to 2021.[16]
Awards and honors
edit- 1998 Pew Scholar in the Biomedical Sciences[17]
- 2012 AHA Basic Science Research Prize[18]
- 2015 Lucian Award[18]
- 2019 AHA Merit Award Winner[19][20]
Selected publications
editThis section's use of external links may not follow Wikipedia's policies or guidelines. (January 2021) |
- Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Baines, C. P., Kaiser, R. A., Purcell, N. H., Blair, N. S., Osinska, H., Hambleton, M. A., Brunskill, E. W., Sayen, M. R., Gottlieb, R. A., Dorn, G. W., Robbins, J., & Molkentin, J. D. (2005). Nature, 434(7033), 658–662.
- An acute immune response underlies the benefit of cardiac stem cell therapy. Vagnozzi, RJ; Maillet, M; Sargent, MA; Khalil, H; Johansen, AK Z; Schwanekamp, JA; York, AJ; Huang, V; Nahrendorf, M; Sadayappan, S; et al. Nature. 2020; 577:405-409.
- A thrombospondin-dependent pathway for a protective ER stress response. Lynch, J. M., Maillet, M., Vanhoutte, D., Schloemer, A., Sargent, M. A., Blair, N. S., Lynch, K. A., Okada, T., Aronow, B. J., Osinska, H., Prywes, R., Lorenz, J. N., Mori, K., Lawler, J., Robbins, J., & Molkentin, J. D. (2012). Cell, 149(6), 1257–1268.
- A Tension-Based Model Distinguishes Hypertrophic versus Dilated Cardiomyopathy. Davis, J., Davis, L. C., Correll, R. N., Makarewich, C. A., Schwanekamp, J. A., Moussavi-Harami, F., Wang, D., York, A. J., Wu, H., Houser, S. R., Seidman, C. E., Seidman, J. G., Regnier, M., Metzger, J. M., Wu, J. C., & Molkentin, J. D. (2016). Cell, 165(5), 1147–1159.
- Depletion of skeletal muscle satellite cells attenuates pathology in muscular dystrophy. Boyer, J. G., Huo, J., Han, S., Havens, J. R., Prasad, V., Lin, B. L., Kass, D. A., Song, T., Sadayappan, S., Khairallah, R. J., Ward, C. W., & Molkentin, J. D. (2022). Nature communications, 13(1), 2940.
References
edit- ^ a b c "Jeffery D. Molkentin | Science History Institute | Center for Oral History". oh.sciencehistory.org. Retrieved 2021-01-03.
- ^ a b "Jeffery D. Molkentin biography and affiliation".
- ^ "Cancer Biology Directory | Molgen | UC Cincinnati College of Medicine". Default. Retrieved 2021-01-02.
- ^ "Jeffery Molkentin, PhD | Jain Foundation". www.jain-foundation.org. Retrieved 2021-01-03.
- ^ "Regulation of Cardiac Hypertrophy | Molkentin Lab". www.cincinnatichildrens.org. Retrieved 2021-01-03.
- ^ "Cincinnati Children's launches six Covid-specific research projects". www.bizjournals.com. Retrieved 2021-01-03.
- ^ Huynh, Karina (February 2020). "Stem cell therapy improves heart function by triggering an acute immune response". Nature Reviews Cardiology. 17 (2): 69. doi:10.1038/s41569-019-0327-6. ISSN 1759-5010. PMID 31827260.
- ^ Johnson, Carolyn Y. "Benefits of stem cell heart therapy may have nothing to do with stem cells, a study on mice suggests". Washington Post. ISSN 0190-8286. Retrieved 2021-01-03.
- ^ "Scopus preview - Molkentin, Jeffery D. - Author details - Scopus". www.scopus.com. Retrieved 2023-12-24.
- ^ "Jeffery D Molkentin". scholar.google.com. Retrieved 2021-01-02.
- ^ "research.com molkentin ranking". research.com.
- ^ Vagnozzi, Ronald J.; Maillet, Marjorie; Sargent, Michelle A.; Khalil, Hadi; Johansen, Anne Katrine Z.; Schwanekamp, Jennifer A.; York, Allen J.; Huang, Vincent; Nahrendorf, Matthias; Sadayappan, Sakthivel; Molkentin, Jeffery D. (January 2020). "An acute immune response underlies the benefit of cardiac stem cell therapy". Nature. 577 (7790): 405–409. doi:10.1038/s41586-019-1802-2. ISSN 1476-4687. PMC 6962570.
- ^ Karch, J.; Molkentin, J. D. (2014-07-07). "Identifying the components of the elusive mitochondrial permeability transition pore". Proceedings of the National Academy of Sciences. 111 (29): 10396–10397. Bibcode:2014PNAS..11110396K. doi:10.1073/pnas.1410104111. ISSN 0027-8424. PMC 4115577. PMID 25002521.
- ^ Williams Ruth (2014-01-17). "Jeffery Molkentin". Circulation Research. 114 (2): 239–241. doi:10.1161/CIRCRESAHA.113.303225. PMID 24436426.
- ^ Davis, Jennifer; Davis, L. Craig; Correll, Robert N.; Makarewich, Catherine A.; Schwanekamp, Jennifer A.; Moussavi-Harami, Farid; Wang, Dan; York, Allen J.; Wu, Haodi; Houser, Steven R.; Seidman, Christine E.; Seidman, Jonathan G.; Regnier, Michael; Metzger, Joseph M.; Wu, Joseph C. (2016-05-19). "A Tension-Based Model Distinguishes Hypertrophic versus Dilated Cardiomyopathy". Cell. 165 (5): 1147–1159. doi:10.1016/j.cell.2016.04.002. ISSN 1097-4172. PMC 4874838. PMID 27114035.
- ^ "Jeffery D. Molkentin". HHMI.org. Retrieved 2021-01-02.
- ^ "Jeffery D. Molkentin, Ph.D." miRagen Therapeutics, Inc. Retrieved 2021-01-03.
- ^ a b Ince Susan (2015-08-28). "2015 Lucian Award". Circulation Research. 117 (6): 498–501. doi:10.1161/CIRCRESAHA.115.307326. PMID 26316606.
- ^ "Cincinnati Children's scientist lands $1M for 'revolutionary' heart research". www.bizjournals.com. Retrieved 2021-01-03.
- ^ "Jeffery D. Molkentin Ph.D." American Heart Association. Retrieved 2021-01-03.